

Electronic Supplementary Material

International Journal of Clinical Oncology

Adverse events of hepatic function disorder in Japanese patients with radically unresectable or metastatic renal cell carcinoma treated with pembrolizumab plus axitinib: a post-marketing surveillance study

Mototsugu Oya¹, Shotaro Yasuoka², Takuto Tokudome², Toshihiko Minegishi², Masahiro Hamada³, Masahiko Ozaki³, Shinichiroh Maekawa³, Yuichiro Ito²

1. Department of Urology, Keio University School of Medicine, Tokyo, Japan
2. Oncology Medical Affairs, MSD K.K., Tokyo, Japan
3. Japan Pharmacovigilance, MSD K.K., Tokyo, Japan

Corresponding author

Takuto Tokudome

Address: Oncology Medical Affairs, MSD K.K., 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo 102-8667, Japan

Tel: +81-3-6272-1000

E-mail: takuto.tokudome@merck.com

Online Resource 1. Background factors associated with AEs of hepatic function disorder for which a causal relationship could not be ruled out with pembrolizumab

For liver function tests (AST, ALT, ALP, γ -GTP, and T-Bil), blood samples were taken and analyzed before the first dose of treatment.

Abbreviations: AEs, adverse events; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence interval; γ -GTP, gamma-glutamyl transpeptidase; IMDC, International Metastatic RCC Database Consortium; KPS, Karnofsky Performance Status; T-Bil, total bilirubin.

